March 31, 2008 – Suven Life Sciences Ltd has announced that two product patents were granted in Mexico and Korea for two of their new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases and these patents are valid until 2023.
These granted patents are exclusive intellectual property of Suven and are achieved through the exclusive internal discovery research efforts. Products out of these inventories, which are in pre-clinical development, may be out-licensed at the stage of clinical phase-I or phase-II stage.
"We are very pleased by the issuance of these patents to Suven for our drug candidates that are being developed for CNS disorders which targets an $18 billion potential market opportunity globally" says Venkat Jasti, CEO of Suven.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like attention deficient hyperactivity, Alzheimer's, Parkinson, Schizophrenia and Huntington's.
No comments:
Post a Comment